NCT04332640CompletedNot Applicable
Clinical Investigation of the Next Generation Phaco System (VERITAS Vision System)
Johnson & Johnson Surgical Vision, Inc.2 sites in 2 countries79 target enrollmentStarted: September 28, 2020Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 79
- Locations
- 2
- Primary Endpoint
- Proportion of Eyes With Surgeon Satisfaction Rating Score of 4 or 5
Study Overview
Brief Summary
This study is a prospective, open-label clinical study of the VERITAS Vision System.
The study will be conducted at up to three sites, with minimum 55 eyes and up to 150 eyes to be treated. The investigator or designee will perform the cataract surgery with the VERITAS Vision System on the subjects. The data from the system log files, the questionnaire, the operative report and other medical records will be used to assess the clinical utilization of the VERITAS Vision System.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 22 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Minimum 22 years of age.
- •Cataracts for which cataract extraction and posterior chamber IOL implantation have been planned.
- •Availability, willingness, ability and sufficient cognitive awareness to comply with study requirements, examination procedures, and visits.
- •Be willing to provide informed consent and authorization to disclose protected health information or equivalent documentation necessary to comply with applicable privacy laws pertaining to medical procedures in the governing countries.
Exclusion Criteria
- •Expected surgical difficulties at the time of cataract extraction, which may increase the potential for complications (e.g., persistent bleeding, significant iris damage, uncontrolled intraocular pressure change, or significant vitreous prolapse or loss).
- •Subjects with only one good eye (e.g. amblyopic condition etc.).
- •Subjects with conditions associated with increased risk of zonular rupture, including capsular or zonular abnormalities that may lead to IOL decentration, including pseudoexfoliation, trauma, or posterior capsule defects.
- •History or current use of alpha-1 antagonist medication (e.g., Flomax).
- •Any condition which, in the Investigator's opinion, would make it unsafe (for the subject or for the study personnel) to treat the subject as part of this research study or for which cataract surgery is contraindicated.
- •Pupil abnormalities (non-reactive, fixed pupils, or abnormally shaped pupils).
- •Is pregnant, or is breast feeding, or intend to become pregnant during the study.
- •Concurrent participation or expected participation in an interventional (i.e., surgical or pharmaceutical interventional) clinical trial within 14 days prior to study screening.
Arms & Interventions
Next Generation Phaco System
Experimental
VERITAS Vision System
Intervention: VERITAS Vision System (Device)
Outcomes
Primary Outcomes
Proportion of Eyes With Surgeon Satisfaction Rating Score of 4 or 5
Time Frame: 1 day postoperative
Surgeons rated the following Questionnaire items regarding satisfaction with the VERITAS Vision System, using 1 - 5 scale (acceptability considered favorable for scores of 4 and 5, where 4 is Satisfied and 5 is Very Satisfied)
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Not Applicable
Prospective, Randomized Controlled Study to Evaluate the Effect of Artificial Intelligence Assisted Optical Diagnosis of Advanced AdenomasAdvanced AdenomaNCT05568992Shanghai Jiao Tong University School of Medicine120
Recruiting
Not Applicable
A Phase I Feasibility Study of an Intracortical Visual Prosthesis (ICVP) for People With BlindnessOptic Nerve DiseasesPhotoreceptor DegenerationOcular InjuryBlindness,AcquiredNCT04634383Illinois Institute of Technology5
Terminated
Not Applicable
Magnetic Resonance Temperature Imaging & Imaging-Guided Laser Induced Thermal Therapy for Treatment of Metastatic Brain TumorsBrain TumorNCT00720837M.D. Anderson Cancer Center6
Withdrawn
Not Applicable
Implantation of a Trifocal Hydrophobic IOL in Patients That Underwent Refractive SurgeryPresbyopiaLens OpacitiesCataractNCT04054427Beaver-Visitec International, Inc.
Unknown
Phase 1
A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF TherapyAge Related Macular DegenerationNCT00809419NeoVista32